Trial Profile
A Phase I Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Globalagliatin Hydrochloride After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Globalagliatin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Yabao Pharmaceutical Group
- 30 Oct 2020 Results published in the Clinical Drug Investigation
- 02 Jan 2020 Status changed from recruiting to completed.
- 01 Feb 2018 New trial record